Abeona Therapeutics (NASDAQ:ABEO) Director Mark Alvino Sells 13,500 Shares

by · The Markets Daily

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) Director Mark Alvino sold 13,500 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $5.23, for a total value of $70,605.00. Following the completion of the transaction, the director owned 48,752 shares of the company’s stock, valued at approximately $254,972.96. This represents a 21.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Alvino also recently made the following trade(s):

  • On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $4.74, for a total value of $71,100.00.

Abeona Therapeutics Stock Performance

Shares of ABEO stock remained flat at $5.31 during trading hours on Wednesday. 1,194,794 shares of the stock were exchanged, compared to its average volume of 1,277,038. The stock has a 50 day simple moving average of $5.04 and a two-hundred day simple moving average of $5.64. The firm has a market capitalization of $287.75 million, a price-to-earnings ratio of 4.32 and a beta of 1.12. Abeona Therapeutics Inc. has a one year low of $3.93 and a one year high of $7.54. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, equities research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its position in shares of Abeona Therapeutics by 14.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock valued at $17,455,000 after purchasing an additional 381,357 shares during the last quarter. Vanguard Group Inc. grew its position in Abeona Therapeutics by 3.8% during the third quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock valued at $13,743,000 after acquiring an additional 95,878 shares during the last quarter. Boone Capital Management LLC purchased a new position in shares of Abeona Therapeutics during the second quarter worth approximately $7,126,000. Geode Capital Management LLC raised its position in Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after purchasing an additional 623,243 shares during the period. Finally, Kennedy Capital Management LLC lifted its stake in Abeona Therapeutics by 56.4% in the third quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock worth $5,549,000 after purchasing an additional 378,860 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ABEO. Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Weiss Ratings lowered Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.00.

View Our Latest Analysis on Abeona Therapeutics

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Read More